Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Anika Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Anika Therapeutics, Inc.’s stock price such as:

• Anika Therapeutics, Inc.’s current stock price and volume
• Why Anika Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ANIK from analysts
• ANIK’s stock price momentum as measured by its relative strength

About Anika Therapeutics, Inc. (ANIK)

Before we jump into Anika Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Want to learn more about Anika Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Anika Therapeutics, Inc..

Anika Therapeutics, Inc.’s Stock Price as of Market Close

As of May 28, 2026, 1:52 PM, CST, Anika Therapeutics, Inc.’s stock price was $14.845.

Anika Therapeutics, Inc. is up 0.24% from its previous closing price of $14.810.

During the last market session, Anika Therapeutics, Inc.’s stock traded between $14.730 and $14.930. Currently, there are approximately 13.53 million shares outstanding for Anika Therapeutics, Inc..

Anika Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Anika Therapeutics, Inc. Stock Price History

Anika Therapeutics, Inc.’s (ANIK) price is currently up 19.24% so far this month.

During the month of May, Anika Therapeutics, Inc.’s stock price has reached a high of $15.710 and a low of $13.510.

Over the last year, Anika Therapeutics, Inc. has hit prices as high as $16.240 and as low as $7.870. Year to date, Anika Therapeutics, Inc.’s stock is up 54.47%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Anika Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 27, 2026, there was 1 analyst who downgraded Anika Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Anika Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Anika Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Anika Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Anika Therapeutics, Inc. (ANIK) by visiting AAII Stock Evaluator.

Relative Price Strength of Anika Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 27, 2026, Anika Therapeutics, Inc. has a weighted four-quarter relative price strength of 3.43%, which translates to a Momentum Score of 70 and is considered to be Strong.

Want to learn more about how Anika Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Anika Therapeutics, Inc. Stock Price: Bottom Line

As of May 28, 2026, Anika Therapeutics, Inc.’s stock price is $14.845, which is up 0.24% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Anika Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.